I don’t own AGN. I sold AGN 2 months ago because of the issue of glutamate and the cross reactivity of the GLN2b and GLN2A receptor. It will work because NA-1 already proved up its mechanism of action and the also NA-1 already proved up the mechanism of action of NYR. Inhibiting calcium influx into neurons reducing brain injury is already proven for NYR and AGN will show the same shortly
NA-1 managed to get a response in humans but has a 10 min infusion period with 10 min half life due to the risk of side effects. NYR has 6 hour infusion time now due to it having a very good safety profile and has nothing to do with glutamate
NYR has a bigger market potential then AGN and treats multiple issues of stroke simultaneously because of it avoiding glutamate and only targeting the calcium ion channel receptors which in turn does the exact same thing as Na-1 and AGN.
NYR Price at posting:
19.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)